文献速递细菌感染、耐药与抗菌药物医院感染防控

2019-2020年台湾北部某医学中心菌血症万古霉素耐药屎肠球菌分离株的分子流行病学及SC5005与其他对照药物对分离株的体外活性

Molecular epidemiology of bacteraemic vancomycin-resistant Enterococcus faecium isolates and in vitro activities of SC5005 and other comparators against these isolates collected from a medical centre in northern Taiwan, 2019-2020.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

研究分析了2019-2020年台湾北部某医学中心262株菌血症万古霉素耐药屎肠球菌(VREfm)的分子流行病学,并检测其对最后线抗生素及新药SC5005的体外敏感性。所有分离株均携带vanA基因,主要序列型为ST17(51%)和ST78(25%),SC5005对所有分离株有效且不易诱导耐药。

要点

  • 262株VREfm均携带vanA基因,最常见序列型为ST17(51%,n=134)和ST78(25%,n=65)。
  • SC5005对所有VREfm分离株有效,包括对最后线抗生素非敏感的菌株。
  • SC5005通过破坏并去极化细菌膜杀菌,未检测到耐药性产生。

核心结论

  • 研究提供了2019-2020年台湾北部菌血症VREfm的最新流行病学和耐药特征。
  • SC5005有潜力开发为治疗VREfm感染的新疗法。

研究设计与样本

  • 研究纳入2019-2020年台湾北部某医学中心的262株菌血症VREfm临床分离株。
  • 采用van基因分型、MLST和PFGE进行分子流行病学分析。
  • 采用琼脂稀释法和肉汤微量稀释法测定抗生素及SC5005的敏感性。
  • 采用耐药频率和多次传代耐药试验评估屎肠球菌对SC5005产生耐药的能力。
  • 采用时间杀菌、细菌膜完整性和膜电位试验评估SC5005的作用机制。

主要发现

  • 所有262株VREfm均携带vanA基因。
  • 最常见序列型为ST17(51%,n=134,84个脉冲型),其次是ST78(25%,n=65,54个脉冲型)。
  • 鉴定出4个新ST型(ST2101、ST2102、ST2135和ST2136),并观察到多重耐药ST1885传入台湾。
  • SC5005对所有VREfm分离株有效,包括对最后线抗生素非敏感的菌株。
  • SC5005可破坏并去极化细菌膜以杀死屎肠球菌,未检测到耐药性。

关键数值与推荐

  • 262株VREfm均携带vanA基因。
  • ST17占51%(n=134,84个脉冲型),ST78占25%(n=65,54个脉冲型)。
  • SC5005对所有VREfm分离株有效,包括对最后线抗生素非敏感的菌株。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The global prevalence of vancomycin-resistant Enterococcus faecium (VREfm) highlights the need for new anti-enterococcal agents. Here, we assessed the molecular epidemiology of clinical VREfm bacteraemic isolates from a medical centre in northern Taiwan in 2019-2020 and to evaluate their susceptibility to last-line antibiotics and a new antimicrobial agent, SC5005. METHODS: The molecular epidemiology of VREfm was investigated using van genotyping, MLST and PFGE. The susceptibilities of VREfm strains to antibiotics and SC5005 were determined using the agar dilution and broth microdilution methods. The capability of E. faecium to develop resistance to antibiotics and SC5005 was evaluated using frequency of resistance and multipassage resistance assays. The mode of action of SC5005 was assessed by time-kill, bacterial membrane integrity and membrane potential assays. RESULTS: All 262 VREfm isolates harboured vanA gene, and the most prevalent sequence type was ST17 (51%, n = 134, 84 pulsotypes), followed by ST78 (25%, n = 65, 54 pulsotypes). Additionally, we identified four new STs (ST2101, ST2102, ST2135 and ST2136) and observed the arrival of multidrug-resistant ST1885 in Taiwan. Moreover, SC5005 was effective against all VREfm isolates, including those non-susceptible to last-line antibiotics. SC5005 can disrupt and depolarize the bacterial membrane to kill E. faecium without detectable resistance. CONCLUSIONS: The findings provide insights into the latest epidemiology and resistance profiles of bacteraemic-causing VREfm in northern Taiwan. Additionally, SC5005 has the potential for development as a new therapeutic to treat VREfm infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Wan TW, Yeo HH, Lee TF, et al. Molecular epidemiology of bacteraemic vancomycin-resistant Enterococcus faecium isolates and in vitro activities of SC5005 and other comparators against these isolates collected from a medical centre in northern Taiwan, 2019-2020. J Antimicrob Chemother. 2023. PMID: 36527680. doi:10.1093/jac/dkac414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。